Challenges in Alzheimer’s Drug Development: Failures, Therapeutic Barriers and Clinical Translation

¹ Assistant Professor, School of Pharmacy, RK University, Rajkot, Gujarat, India
² Research Scholar, V.V.P. Engineering College, Rajkot, Gujarat, India
³ Associate Professor, School of Pharmacy, RK University, Rajkot, Gujarat, India

^* Corresponding Author: This email address is being protected from spambots. You need JavaScript enabled to view it.

Published online: 21 January 2026

Abstract

Alzheimer's disease (AD) continues to pose a significant challenge in pharmaceutical research, with drug development marked by high attrition rates despite decades of investigation. Numerous therapeutic candidates, particularly those targeting amyloid-beta and tau proteins, have shown promise in preclinical studies but failed to produce substantial clinical benefits. Most failures occur in late-stage trials, especially Phase II and III, due to limited therapeutic efficacy, unforeseen adverse effects, or inability to alter disease progression. The complex and multifactorial nature of AD pathology including neuroinflammation, synaptic degeneration, and metabolic disturbances makes developing a single curative treatment highly difficult. This review examines the underlying reasons for these setbacks, focusing on clinical trial outcomes and the limitations of previous pharmacological approaches. Examples of unsuccessful candidates underscore persistent gaps in understanding disease mechanisms and therapeutic targeting. Addressing these challenges requires a paradigm shift toward early diagnosis, patient-specific precision medicine, and combination therapy strategies. Additionally, advancing biomarker discovery, employing adaptive and innovative trial designs, and exploring novel molecular targets may improve the likelihood of clinical success. By integrating these approaches, future research holds the potential to overcome existing barriers and deliver effective interventions for AD.